Vanguard Group Inc. Has $92.72 Million Position in Vera Therapeutics, Inc. $VERA

Vanguard Group Inc. grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 6.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,190,653 shares of the company’s stock after purchasing an additional 189,545 shares during the quarter. Vanguard Group Inc. owned about 5.00% of Vera Therapeutics worth $92,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vestal Point Capital LP grew its stake in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after purchasing an additional 600,000 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Vera Therapeutics by 7.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,294,958 shares of the company’s stock worth $30,513,000 after buying an additional 92,149 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Vera Therapeutics by 89.3% during the 2nd quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock worth $16,832,000 after buying an additional 336,978 shares in the last quarter. MPM Bioimpact LLC grew its position in shares of Vera Therapeutics by 35.4% during the 2nd quarter. MPM Bioimpact LLC now owns 563,075 shares of the company’s stock worth $13,266,000 after buying an additional 147,356 shares during the period. Finally, Capricorn Fund Managers Ltd bought a new stake in shares of Vera Therapeutics in the 3rd quarter valued at $13,097,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 2.0%

Vera Therapeutics stock opened at $38.85 on Friday. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -8.34 and a beta of 1.17. The firm’s fifty day moving average price is $45.12 and its two-hundred day moving average price is $36.00. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the prior year, the business posted ($0.72) EPS. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Trending Headlines about Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Vera appointed Christopher Hite to its Board of Directors — adds seasoned corporate and financial strategy experience that can help with capital markets strategy and investor credibility. Vera Therapeutics Appoints Christopher Hite to Board of Directors
• Positive Sentiment: HC Wainwright raised long‑range EPS views for FY2029 and FY2030 (FY2029 to $8.43, FY2030 to $9.88), reflecting an expectation of strong longer‑term upside if Vera’s pipeline succeeds — supportive for longer‑term bulls. HC Wainwright long‑term estimates (MarketBeat)
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and a $110 price target on VERA — that provides institutional support but the target is far above current levels and depends on pipeline success. HC Wainwright rating and price target (MarketBeat)
• Negative Sentiment: HC Wainwright sharply cut near‑term EPS forecasts across 2026 quarters and lowered FY2026 and FY2027 estimates (examples: Q1 2026 to ($1.35) from ($0.98); FY2026 to ($4.84) from ($3.18)), signaling larger expected losses or slower progress than previously modeled — a clear negative for short‑term share performance. HC Wainwright cuts to 2026/2027 estimates (MarketBeat)
• Negative Sentiment: Downward revisions to FY2028 were also issued (FY2028 from $3.74 to $2.04), which reduces the near‑to‑medium‑term revenue/profitability path that investors may have been pricing in. HC Wainwright FY2028 revision (MarketBeat)

Insider Activity

In other news, insider William D. Turner sold 2,187 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the sale, the insider directly owned 45,313 shares of the company’s stock, valued at $1,902,239.74. This represents a 4.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO David Lee Johnson sold 2,579 shares of Vera Therapeutics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the transaction, the chief operating officer directly owned 45,727 shares in the company, valued at approximately $1,919,619.46. The trade was a 5.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 33,490 shares of company stock worth $1,405,910. Company insiders own 16.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Bank of America boosted their target price on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. Pivotal Research set a $73.00 target price on Vera Therapeutics in a research note on Friday, December 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.80.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.